NVNO
enVVeno Medical Corporation

8,779
Loading...
Loading...
News
all
press releases
NVNO's Shares Decline on Unfavorable FDA Review Outcome for VenoValve
enVVeno Medical shares plunge after the FDA rejects its VenoValve PMA, citing insufficient trial data and safety concerns tied to the surgical procedure.
Zacks·1mo ago
News Placeholder
More News
News Placeholder
This Medical Device Stock Just Plunged A Whopping 71% Today – Do You Own It?
enVVeno Medical Corporation CEO Robert Berman said that the company will continue to work with the FDA on new criteria to demonstrate the safety and effectiveness of its VenoValve device.
Stocktwits·1mo ago
News Placeholder
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session
read more...
Benzinga·1y ago
News Placeholder
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, March 21st at 12:00 PM ETIRVINE, CA / ACCESSWIRE / March 15, 2024 / enVVeno Medical Corporation...
Accesswire·2y ago
News Placeholder
BeyondSpring, enVVeno Medical, Aptorum Group among healthcare movers
BeyondSpring, enVVeno Medical, Aptorum Group among healthcare movers...
SeekingAlpha.com: All News·2y ago
News Placeholder
enVVeno Medical presents efficacy data from SAVVE U.S. trial for VenoValve
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
97% of VenoValve Study Patients Showing Clinical Improvement at Six Months (as Measured by the Revised Venous Clinical Severity Score (rVCSS))74% of the Study Patients Showing Clinical Meaningful...
Accesswire·2y ago
News Placeholder
enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
$46.4 million cash and investments on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025Topline efficacy data for VenoValve(R) U.S...
Accesswire·2y ago
News Placeholder
Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
IRVINE, CA / ACCESSWIRE / February 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ('enVVeno' or the 'Company'), a company setting new standards of care for the treatment of venous disease...
Accesswire·2y ago
News Placeholder
12 titres de soins de sant en mouvement lors de la session apr s-cl ture le 13/02/2024
Gagnants Le titre Clene (NASDAQ:CLNN) a augment mardi de 18,20% 0,50 dollars lors de la session after-market. L'action Larimar Therapeutics (NASDAQ:LRMR) a augment de 14,41% 10 dollars. Le...
Benzinga·2y ago

Latest NVNO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.